The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Analysts say the drug could emerge as a potential competitor to Merck’s blockbuster immunotherapy Keytruda. Keytruda is ...

Merck & Co reported stronger-than-expected quarterly earnings thanks to rising Keytruda sales. However, Gardasil's weak ...

There isn't enough evidence to support the use of Merck & Co/MSD's Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...